GlassScriptPhysician profile
Austin Michael Cole
NPI 1154896207
$2,395.94
in general payments reported to CMS, 2019-2025
20 companies · $903 in 2025
The $903 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.24 · 2023: $486 · 2024: $968 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.71 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.75 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $312.40 | 2023-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $248.08 | 2023-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $224.75 | 2023-2025 | Farxiga, Atacand |
| Amgen INC. | $181.44 | 2023-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $159.34 | 2024 | Xarelto |
| Scpharmaceuticals INC. | $125.85 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $122.59 | 2023-2024 | |
| Bridgebio Pharma, INC. | $118.75 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $91.69 | 2023-2025 | Eliquis, Camzyos |
| Pfizer INC. | $74.68 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.30 | 2023-2025 | |
| Philips North America LLC | $62.60 | 2023-2025 | (5091) Amb Mon & Diag Und, Mcot |
| Corcept Therapeutics | $57.20 | 2025 | Korlym |
| Atricure, INC. | $47.43 | 2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $39.03 | 2024-2025 | Impella |
| Abbvie INC. | $38.24 | 2021 | |
| Esperion Therapeutics, INC. | $37.92 | 2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $30.38 | 2024 | Arcalyst |
| Boston Scientific Corporation | $18.52 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.